DCPH - Deciphera Pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

1.965B

Cash

272.5M

Avg Qtr Burn

-37.96M

Short % of Float

8.45%

Insider Ownership

28.48%

Institutional Own.

72.03%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Qinlock (ripretinib) (KIT & PDGFRA inhibitor) Details GIST (Gastrointestinal stromal tumors) (fourth-line)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vimseltinib (DCC-3014) (CSF1R inhibitor) Details Tenosynovial Giant Cell Tumors, Cancer	NDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Qinlock (Ripretinib) Details Gastrointestinal stromal tumors	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vimseltinib (DCC-3014) (CSF1R inhibitor) Details Cancer, Tenosynovial Giant Cell Tumors	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DCC-3116 (Inhibitor of ULK) + trametinib, sotorasib & binimetin Details Solid tumor/s, Cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DCC-3116 (Inhibitor of ULK)+encorafenib & cetuximab Details Solid tumor/s, Colorectal cancer , Cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DCC-3116 (Inhibitor of ULK)+Qinlock Details Solid tumor/s, Gastrointestinal stromal tumors	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rebastinib (TIE2 inhibitor) + Paclitaxel Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.